cuvitru normal immunoglobulin (human) infusion 20% for subcutaneous use in glass vial
takeda pharmaceuticals australia pty ltd - normal immunoglobulin, quantity: 1 g - solution - excipient ingredients: glycine; water for injections - cuvitru is indicated as replacement therapy in adult and paediatric patients for,? primary immunodeficiency diseases (pid) and,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
flebogamma 10% dif normal immunoglobulin (human) intravenous use injection vial
grifols australia pty ltd - normal immunoglobulin, quantity: 5 g - injection, solution - excipient ingredients: sorbitol; human immunoglobulin a; water for injections - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.
flebogamma 10% dif normal immunoglobulin (human) 20g/200ml intravenous use injection vial
grifols australia pty ltd - normal immunoglobulin, quantity: 20 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.
flebogamma 10% dif normal immunoglobulin (human) 10g/100ml intravenous use injection vial
grifols australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.
csl cmv immunoglobulin vf (human) 1.5 million units/vial injection
csl behring australia pty ltd - human immunoglobulin g, quantity: 50 mg/ml; cytomegalovirus immunoglobulin, quantity: 1500000 u - injection, intravenous infusion - excipient ingredients: water for injections; human immunoglobulin a; maltose - cmv immunoglobulin-vf is indicated for the prevention of cmv infection following bone marrow and renal transplants. specifically, the product is indicated when the recipient is seronegative for cmv and receives a graft from a cmv positive donor. cmv immunoglobulin-vf may also be a helpful adjunct to therapy in patients with established cmv infection, e.g. cmv pneumonitis.
hepacaf 5 000 iu inf. sol. (pwdr. + solv.) i.v.
lfb biomedicaments s.a. - human hepatitis b immunoglobulin 5000 iu/100 ml - powder and solvent for solution for infusion - 5000 iu - human anti-hepatitis b immunoglobulin 5000 iu - hepatitis b immunoglobulin
neohepatect 50 iu/ml inf. sol. i.v. vial
biotest pharma gmbh - human hepatitis b immunoglobulin 50 iu/ml - solution for infusion - 50 iu/ml - human anti-hepatitis b immunoglobulin - hepatitis b immunoglobulin
neohepatect 50 iu/ml inf. sol. i.v. vial
biotest pharma gmbh - human hepatitis b immunoglobulin 50 iu/ml - solution for infusion - 50 iu/ml - human anti-hepatitis b immunoglobulin - hepatitis b immunoglobulin
neohepatect 50 iu/ml inf. sol. i.v. vial
biotest pharma gmbh - human hepatitis b immunoglobulin 50 iu/ml - solution for infusion - 50 iu/ml - human anti-hepatitis b immunoglobulin - hepatitis b immunoglobulin
neohepatect 50 iu/ml inf. sol. i.v. vial
biotest pharma gmbh - human hepatitis b immunoglobulin 50 iu/ml - solution for infusion - 50 iu/ml - human anti-hepatitis b immunoglobulin - hepatitis b immunoglobulin